Works matching IS 25094254 AND DT 2025 AND VI 9 AND IP 1

Results: 14
    1
    2
    3
    4

    Cost-Effectiveness of Three Different New-Generation Drug-Eluting Stents in the Randomised BIO-RESORT Trial at 3 Years: Cost-Effectiveness of Three DES: E. H. Ploumen et al.

    Published in:
    PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 137, doi. 10.1007/s41669-024-00539-x
    By:
    • Ploumen, Eline H.;
    • Wolcherink, Martijn J. Oude;
    • Buiten, Rosaly A.;
    • Pinxterhuis, Tineke H.;
    • Doggen, Carine J. M.;
    • Schotborgh, Carl E.;
    • Danse, Peter W.;
    • Scholte, Martijn;
    • van Houwelingen, K. Gert;
    • Zocca, Paolo;
    • Pouwels, Xavier G. L. V.;
    • von Birgelen, Clemens
    Publication type:
    Article
    5

    Health Economic Evaluation of Antimicrobial Stewardship, Procalcitonin Testing, and Rapid Blood Culture Identification in Sepsis Care: A 90-Day Model-Based, Cost-Utility Analysis: Sepsis Care Economic Analysis: Wendy I. Sligl et al.

    Published in:
    PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 15, doi. 10.1007/s41669-024-00538-y
    By:
    • Sligl, Wendy I.;
    • Yan, Charles;
    • Round, Jeff;
    • Wang, Xiaoming;
    • Chen, Justin Z.;
    • Boehm, Cheyanne;
    • Fong, Karen;
    • Crick, Katelynn;
    • Clua, Míriam Garrido;
    • Codan, Cassidy;
    • Dingle, Tanis C.;
    • Prosser, Connie;
    • Chen, Guanmin;
    • Tse-Chang, Alena;
    • Garros, Daniel;
    • Zygun, David;
    • Opgenorth, Dawn;
    • Conly, John M.;
    • Doig, Christopher J.;
    • Lau, Vincent I.
    Publication type:
    Article
    6
    7
    8
    9

    Mortality, Clinical Complications, and Healthcare Resource Utilization Associated with Managing Transfusion-Dependent β-Thalassemia and Sickle Cell Disease with Recurrent Vaso-occlusive Crises in Italy: Burden of TDT and SCD with Recurrent VOCs in Italy: C. Udeze et al

    Published in:
    PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 115, doi. 10.1007/s41669-024-00532-4
    By:
    • Udeze, Chuka;
    • Dovizio, Melania;
    • Veronesi, Chiara;
    • Esposti, Luca Degli;
    • Li, Nanxin;
    • Dang, Thi Xuan Mai Patricia;
    • Forni, Gian Luca
    Publication type:
    Article
    10
    11
    12

    Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand: SGLT2i for Thai Diabetes with HF Patients: T. Kongmalai et al.

    Published in:
    PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 69, doi. 10.1007/s41669-024-00526-2
    By:
    • Kongmalai, Tanawan;
    • Prawjaeng, Juthamas;
    • Hadnorntun, Phorntida;
    • Leelahavarong, Pattara;
    • Chaikledkaew, Usa;
    • Thakkinstian, Ammarin;
    • Srinonprasert, Varalak
    Publication type:
    Article
    13

    Healthcare Resource Utilization and Associated Costs During the First 5 Years After Diagnosis and at the End of Life: A Nationwide Cohort Study of Patients with Multiple Myeloma in Finland: Healthcare Resource Use and Costs of Multiple Myeloma in Finland: M. Kosunen et al

    Published in:
    PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 57, doi. 10.1007/s41669-024-00524-4
    By:
    • Kosunen, Mikko;
    • Ruotsalainen, Jarno;
    • Kallio, Alvar;
    • Metsä, Roope;
    • Raittinen, Paavo;
    • Lehmus, Leena;
    • Korhonen, Maarit J.;
    • Purmonen, Timo
    Publication type:
    Article
    14

    Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study: Cost Effectiveness of Vedolizumab as First-Line Biologic in Inflammatory Bowel Diseases: A. Fischer et al

    Published in:
    PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 41, doi. 10.1007/s41669-024-00523-5
    By:
    • Fischer, Aren;
    • Mac, Stephen;
    • Freiman, Erica Stivelman;
    • Marshall, John K.;
    • Rand, Kim;
    • Ramos-Goñi, Juan M.
    Publication type:
    Article